AstraZeneca (CHIX:AZNL) Construction In Progress : £0 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is AstraZeneca Construction In Progress?

AstraZeneca's quarterly construction in progress increased from Sep. 2024 (£0 Mil) to Dec. 2024 (£2,206 Mil) but then declined from Dec. 2024 (£2,206 Mil) to Mar. 2025 (£0 Mil).

AstraZeneca's annual construction in progress declined from Dec. 2022 (£2,178 Mil) to Dec. 2023 (£1,616 Mil) but then increased from Dec. 2023 (£1,616 Mil) to Dec. 2024 (£2,206 Mil).

AstraZeneca Construction In Progress Historical Data

The historical data trend for AstraZeneca's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Construction In Progress Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

1,843.63

2,051.46

2,178.11

1,615.55

2,206.10

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Construction In Progress	Get a 7-Day Free Trial															-	-	-	2,206.10	-

AstraZeneca Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (CHIX:AZNl) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZNN:Mexico AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines